抗凝治疗的新兴趋势:对DOACs和内源性凝血途径抑制剂的文献分析
Zhe Zhu1, Rong Huang2, Hongli He1
1School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China.
Naunyn-Schmiedeberg's archives of pharmacology
|June 18, 2025
概括
直接口服抗凝剂 (DOAC) 和新型途径抑制剂正在改变抗凝. 这种文献计量分析绘制了研究趋势,确定了诸如DOAC安全性和新的抗血栓瘤标等关键领域.
科学领域:
- 药理学和血栓瘤研究研究
- 图书统计学和科学趋势分析
背景情况:
- 直接口服抗凝剂 (DOAC) 显著提升了抗凝治疗.
- 新兴的内源性凝血通路的向抑制剂提供了新的治疗维度.
研究的目的:
- 系统地描述抗凝固疗法的不断变化的研究格局.
- 阐明历史发展,研究热点和DOACs和新型途径抑制剂的新兴趋势.
- 确定抗血栓药物开发中的关键贡献者和主要研究前沿.
主要方法:
- 从科学网络核心集合中对1993年出版物 (1990-2024) 进行了全面的文献计量分析.
- 利用CiteSpace和HistCite分析历史特征,主题演变和新兴趋势.
- 确定了领先的国家 (美国,中国,加拿大) 和该领域的主要调查人员.
主要成果:
- 出版物的快速增长,美国,中国和加拿大是主要贡献者.
- 四位主要调查人员 (锦华,利普格雷戈里Y.H.,韦茨杰弗里I.,高纳) 显示出高出版量.
- 确定了三个不同的研究领域:DOAC的临床应用/安全性,用于预防血栓形成的XI因子抑制剂和针对iXase的抗凝固剂.
结论:
- 该研究提供了DOAC和内源途抑制剂在抗血栓治疗中的系统概述.
- 确定了当前的研究重点和新兴趋势,以指导未来的抗凝固药物开发.
- 突出了下一代抗凝固药物的新疗法目标.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
924
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
924
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
655
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K


